Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge acts as legal advisers in connection with Duni AB’s admission to the OMX Nordic Stock Exchange in Stockholm
Mandate

Vinge acts as legal advisers in connection with Duni AB’s admission to the OMX Nordic Stock Exchange in Stockholm

November 14, 2007

Vinge is acting as legal advisers in connection with Duni AB’s admission to the stock exchange. Duni AB is indirectly owned by EQT through Duni Holding AB.
The offer comprises 28,200,000 shares, representing 60.0 per cent of the shares and the votes in the company, and will be carried out through the sale of shares by Duni Holding AB. The total value of the offer amounts to MSEK 1,410 which corresponds to a value of outstanding shares in the company of MSEK 2,350.

The partner in charge is Rikard Stenberg assisted by associates Henrik Fritz, Petter Alberts, Ulrich Ziche, Marion Ehmann, Helena Backlund and others.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026